Atrial Fibrillation and Stroke in Cancer Patients

Carlos R. Manrique, J. C. Plana

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Atrial fibrillation (AF) has a significant impact on our society. Currently, this disease is considered a growing epidemic in the world with an estimated 33.5 million cases worldwide in 2010, and the expectation for the number of cases to rise by at least 5% per year. In the same way, the number of patients with AF in the United States is expected to grow from 2.3 million in 2001 to 5.6-6.3 million in 2050. An epidemiological study conducted by Colilla et al. shows an incidence of 1.2 million cases in 2010, with a statistical projection to 2.6 million in 2030. Similar data have been reported in Europe with an estimated prevalence of AF in the general population of approximately 1.5-2% with an elevated economic cost for the healthcare systems. However, the dimension of the real problem could be underestimated in the light of subclinical disease.

Original languageEnglish (US)
Title of host publicationAnticancer Treatments and Cardiotoxicity
Subtitle of host publicationMechanisms, Diagnostic and Therapeutic Interventions
PublisherElsevier Inc.
Pages131-138
Number of pages8
ISBN (Print)9780128025093
DOIs
StatePublished - Dec 6 2016

Fingerprint

Atrial Fibrillation
Stroke
Neoplasms
Epidemiologic Studies
Economics
Delivery of Health Care
Costs and Cost Analysis
Incidence
Population

Keywords

  • Atrial
  • Cancer
  • Fibrillation
  • Patients
  • Stroke

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Manrique, C. R., & Plana, J. C. (2016). Atrial Fibrillation and Stroke in Cancer Patients. In Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions (pp. 131-138). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-802509-3.00019-4

Atrial Fibrillation and Stroke in Cancer Patients. / Manrique, Carlos R.; Plana, J. C.

Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions. Elsevier Inc., 2016. p. 131-138.

Research output: Chapter in Book/Report/Conference proceedingChapter

Manrique, CR & Plana, JC 2016, Atrial Fibrillation and Stroke in Cancer Patients. in Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions. Elsevier Inc., pp. 131-138. https://doi.org/10.1016/B978-0-12-802509-3.00019-4
Manrique CR, Plana JC. Atrial Fibrillation and Stroke in Cancer Patients. In Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions. Elsevier Inc. 2016. p. 131-138 https://doi.org/10.1016/B978-0-12-802509-3.00019-4
Manrique, Carlos R. ; Plana, J. C. / Atrial Fibrillation and Stroke in Cancer Patients. Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions. Elsevier Inc., 2016. pp. 131-138
@inbook{3f84a6de2bb9433ca9e573b2c56706a1,
title = "Atrial Fibrillation and Stroke in Cancer Patients",
abstract = "Atrial fibrillation (AF) has a significant impact on our society. Currently, this disease is considered a growing epidemic in the world with an estimated 33.5 million cases worldwide in 2010, and the expectation for the number of cases to rise by at least 5{\%} per year. In the same way, the number of patients with AF in the United States is expected to grow from 2.3 million in 2001 to 5.6-6.3 million in 2050. An epidemiological study conducted by Colilla et al. shows an incidence of 1.2 million cases in 2010, with a statistical projection to 2.6 million in 2030. Similar data have been reported in Europe with an estimated prevalence of AF in the general population of approximately 1.5-2{\%} with an elevated economic cost for the healthcare systems. However, the dimension of the real problem could be underestimated in the light of subclinical disease.",
keywords = "Atrial, Cancer, Fibrillation, Patients, Stroke",
author = "Manrique, {Carlos R.} and Plana, {J. C.}",
year = "2016",
month = "12",
day = "6",
doi = "10.1016/B978-0-12-802509-3.00019-4",
language = "English (US)",
isbn = "9780128025093",
pages = "131--138",
booktitle = "Anticancer Treatments and Cardiotoxicity",
publisher = "Elsevier Inc.",
address = "United States",

}

TY - CHAP

T1 - Atrial Fibrillation and Stroke in Cancer Patients

AU - Manrique, Carlos R.

AU - Plana, J. C.

PY - 2016/12/6

Y1 - 2016/12/6

N2 - Atrial fibrillation (AF) has a significant impact on our society. Currently, this disease is considered a growing epidemic in the world with an estimated 33.5 million cases worldwide in 2010, and the expectation for the number of cases to rise by at least 5% per year. In the same way, the number of patients with AF in the United States is expected to grow from 2.3 million in 2001 to 5.6-6.3 million in 2050. An epidemiological study conducted by Colilla et al. shows an incidence of 1.2 million cases in 2010, with a statistical projection to 2.6 million in 2030. Similar data have been reported in Europe with an estimated prevalence of AF in the general population of approximately 1.5-2% with an elevated economic cost for the healthcare systems. However, the dimension of the real problem could be underestimated in the light of subclinical disease.

AB - Atrial fibrillation (AF) has a significant impact on our society. Currently, this disease is considered a growing epidemic in the world with an estimated 33.5 million cases worldwide in 2010, and the expectation for the number of cases to rise by at least 5% per year. In the same way, the number of patients with AF in the United States is expected to grow from 2.3 million in 2001 to 5.6-6.3 million in 2050. An epidemiological study conducted by Colilla et al. shows an incidence of 1.2 million cases in 2010, with a statistical projection to 2.6 million in 2030. Similar data have been reported in Europe with an estimated prevalence of AF in the general population of approximately 1.5-2% with an elevated economic cost for the healthcare systems. However, the dimension of the real problem could be underestimated in the light of subclinical disease.

KW - Atrial

KW - Cancer

KW - Fibrillation

KW - Patients

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85027275383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027275383&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-802509-3.00019-4

DO - 10.1016/B978-0-12-802509-3.00019-4

M3 - Chapter

SN - 9780128025093

SP - 131

EP - 138

BT - Anticancer Treatments and Cardiotoxicity

PB - Elsevier Inc.

ER -